Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 20/20 | 1.00 |
| ▸ | KCNK9 | Q9NPC2 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18963277 | 1.00 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18963199 | 0.91 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL29432709 | 0.91 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18963161 | 0.87 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18963158 | 0.87 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18963165 | 0.86 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL29457981 | 0.85 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL20291860 | 0.85 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18963273 | 0.85 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18963206 | 0.84 | KCNK3 (1.00) | KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082731-A1 | INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA | MOSANNA THERAPEUTICS AG (CH) | 2025-04-24 | — | — | WO | disclosed |
| EP-4452246-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023118102-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |
| EP-4175954-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2023-05-10 | — | — | EP | disclosed |
| EP-3965766-A1 | COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |